MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re — examination
For best results when printing this announcement, please click on link below: MaaT Pharma Provides Update on MaaT013 (Xervyteg(®)) Potential Development Plan Following CHMP Negative Opinion After Re-examination The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a neg